MNKD: revenue $109.4M, net income -$19.0M. MNKD swings to operating loss as Afrezza/V-Go sales fall, Furoscix added; UT shift to Tresmi risks royalties

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read

Key Changes

• high

  Subsequent event: On July 23, 2026, the Company entered into a Securities Purchase Agreement with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors an…

  Notes: Subsequent Events view on EDGAR →
• high

  Operating income swung from $5.3M to -$350K (Q2 YoY) as Afrezza revenue fell 7% and V-Go plunged 33% on lower demand, while SG&A doubled to $58.3M for Furoscix commercialization and new product launches.

  Notes: Operating Results verify on EDGAR →
• high

  United Therapeutics may de-prioritize Tyvaso DPI for Tresmi (soft-mist inhaler) and ralinepag DPI, per UT's Feb 2026 earnings call. MNKD has no control over UT's commercialization decisions; Tyvaso DPI royalties could decline materially.

  Risk Factors: UT Strategic Shift verify on EDGAR →